Maelor plc, the specialist critical care pharmaceuticals and devices

Volplex A 4% solution of succinylated gelatin used in operating theatres and wards in patients who require fluid replacement.
OptiFlo UK brand of a range of catheter irrigation solutions.
ContiSol international brand of a range of catheter irrigation solutions.

Development products

Micelle nanotechnology - A drug delivery system which enables insoluble active pharmaceuticals to be solubilised.
Lead development products in this area relate to:
* Interstitial cystitis and chronic pelvic pain (Plethora Solutions)
* Wound care
* Anaesthesiology

Operational highlights announced 1 June 2006

Licensing agreement with Plethora Solutions plc for micelle nanotechnology drug delivery system for use in the treatment of interstitial cystitis and painful bladder syndrome
Volplex UK rights re-acquired and product re-launched successfully. In-market sales for the second half of the year up 35% compared to the first half compared to the first half
OptiFlo UK in-market sales grow by 32% over the previous year
Jump 17%
http://www.maelor.plc.uk

10 May 2007 - Acquisition of Acorus Therapeutics Ltd completed

24 Feb 2004 - signed a major contract for the distribution of
its plasma substitute product,Volplex, in China. The agreement with Helicon Group
Pty Ltd will lead to Volplex being marketed and distributed in China through a network
of sales offices. Helicon is also charged with the regulatory submission, which should
be completed in 2004.

Volplex (succinylated gelatin) is given as an intravenous infusion to substitute
for blood volume lost by patients suffering from the effects of trauma, surgery
or certain medical conditions which result in hypovolaemia (lower than normal
blood volume).

Volplex has expanded its international franchise over the last few months,
gaining regulatory approval in Argentina in December 2003 where it will shortly
be launched. Maelor has established partners in South Africa and Bangladesh
(where regulatory applications have already been submitted) and also in
Australia in preparation for future launches in those markets.

Good TA grapf posted on ADVFN showing the potential of a breakout.

Full acknowledgement to MIKE HARDMAN

http://www.advfn.com/cmn/fbb/thread.php3?id=10990982

Results for year end to March 31st due June 5th. 2007.

They have already stated that they will beat the market's expectations, should see a nice little run up now.

Have a really great day.

BKE seem to be turning the corner...worth a punt.

Great directors...look what they did with COH, from 11P to 50P.

Although they have dropped back a big bounce is on the cards...keep a lookout.

Its always great to have other's view points for the sake of the shareholders I sincerely trust that you are right.

The in the SP of COH since it consolidated has made many shrewd punters a lot of money and as the SP has bottomed since the recent sell-off, there are more profits to be made in the coming months.

RE COH.

As stated its always nice to have a diverse of views on shares.

I have no doubt COH has made money for many and good for them.

Anyone beating the market gets top marks from me.

However its not those that concern me.

In times like this its the poor sods that are now firmly stuck fast, having bought in, as they did, at around 50p.

I simply feel the the Chairman should make some announcement, how ever brief, in order to illuminate the situation as, and I trust you have noticed COH sellers are still quite strong.

If today's mid-price trades where buys then there could be more buys than sells and as the SP did not move then IMHO they were buys.